Daiichi Sankyo logo
Daiichi Sankyo
DSNKY | OTC
Chart Builder DCF Calculator
$17.95
+$0.02 (+0.11%)
At close: Nov 16, 2026, 3:50 PM ET
$18.02
+$0.07 (+0.39%)
After-hours: Nov 16, 2026, 3:02 PM ET

Daiichi Sankyo Company Profile

Company profile explained

Company Profile

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes. Other notable products in this area are prasugrel, an antiplatelet agent; edoxaban, an anticoagulant; olmesartan, an antihypertensive; and pravastatin for hypercholesterolemia. Neurology and Pain Management: Offerings include mirogabalin for pain relief, lacosamide as an anti-epileptic agent, memantine for Alzheimer's disease, and loxoprofen, an anti-inflammatory analgesic. Bone Health: Denosumab is available for conditions like osteoporosis and other bone disorders. Gastrointestinal and Other Specialized Treatments: This category features esomeprazole for ulcer treatment, silodosin for dysuria, and ferric carboxymaltose and iron sucrose injections to address anemia. Infectious Diseases and Immunology: Daiichi Sankyo markets laninamivir for anti-influenza treatment, levofloxacin as an antibacterial agent, and a range of vaccines including adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. Beyond prescription medications, the company also supplies a variety of consumer healthcare products: Over-the-Counter Remedies: Lulu, a combination cold remedy, and Loxonin S, an antipyretic/anti-inflammatory analgesic. Dermatology and Personal Care: Transino, aimed at improving melasma and treating spots/freckles; Minon skincare products; and oral care solutions like Breath Labo and Clean Dental. Furthermore, Daiichi Sankyo's operations extend to pharmaceuticals and drugs for animals, cosmetics, medical equipment, various food products, drinking water, and active pharmaceutical ingredients (APIs) and intermediates. The company is also engaged in strategic collaborations, notably with Guardant Health to develop Guardant360 CDx, a companion diagnostic specifically for Enhertu in patients with advanced metastatic non-small cell lung cancer. Established in 1899, Daiichi Sankyo Company, Limited maintains its corporate headquarters in Tokyo, Japan.

Key Executives

Name Position
Hiroyuki Okuzawa President, Chief Executive Officer & Representative Director
Joji Nakayama Senior Adviser
Joseph Kenneth Keller Head of Oncology Business Unit & Global Oncology Business and Director
Matt Allegrucci Head of Global Compliance & Risk Management and Chief Compliance Officer
Naoto Tsukaguchi Senior Executive Officer, Head of Global Legal & IP, GC
Stuart Mackey Global Head of Business Development & Director
Takashi Matsumoto Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director
Tetsuya Ohira Corporate Officer, Head of Business Transformation & CTO
Thierry Gruson Head of Global Oncology Marketing
Tomohiro Kodama Senior Executive Officer, Head of Global Corporate Planning & Management and CFO
Daiichi Sankyo
Daiichi Sankyo logo
Country Japan
IPO Date Dec 12, 2008
Industry Drug Manufacturers - General
Sector Healthcare
Employees 20,171
CEO Hiroyuki Okuzawa

Contact Details

Daiichi Sankyo Building A/B Tokyo, TY 103-8426 Japan

Stock Details

Ticker Symbol DSNKY
Exchange OTC
Fiscal Year n/a
Reporting Currency USD
CIK Code n/a
CUSIP Number 23381D102
ISIN Number US23381D1028
SIC Code n/a

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.